Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Marizyme ( (MRZM) ) has provided an update.
On April 9, 2026, Marizyme, Inc.’s board determined that transferring all or substantially all of the company’s assets through an assignment for the benefit of creditors was in its best interests and authorized execution of a general assignment agreement with assignee Peter Hurwitz. The company entered into this Assignment Agreement on April 14, 2026, and the assignee plans to commence the state court assignment proceeding in Palm Beach County, Florida, on or before April 17, 2026, marking a major shift in Marizyme’s operations and signaling severe financial distress with significant implications for creditors and other stakeholders.
More about Marizyme
Marizyme, Inc. is a healthcare company operating in the medical technology and life sciences sector. The firm focuses on developing and commercializing specialized therapeutic and diagnostic solutions, positioning itself within niche medical markets that rely on advanced clinical products and innovation-driven growth.
Technical Sentiment Signal: Sell
Current Market Cap: $132
For detailed information about MRZM stock, go to TipRanks’ Stock Analysis page.